CL2017001543A1 - Formulaciones farmacéuticas de inhibidores de la cinasa relacionada con tropomiosina (trk) - Google Patents

Formulaciones farmacéuticas de inhibidores de la cinasa relacionada con tropomiosina (trk)

Info

Publication number
CL2017001543A1
CL2017001543A1 CL2017001543A CL2017001543A CL2017001543A1 CL 2017001543 A1 CL2017001543 A1 CL 2017001543A1 CL 2017001543 A CL2017001543 A CL 2017001543A CL 2017001543 A CL2017001543 A CL 2017001543A CL 2017001543 A1 CL2017001543 A1 CL 2017001543A1
Authority
CL
Chile
Prior art keywords
pharmaceutical formulations
trk
related kinase
tropomyosin
kinase inhibitors
Prior art date
Application number
CL2017001543A
Other languages
English (en)
Inventor
Harvey Lieberman
Donglai Yang
C Michael Philbrook
Michael Santos
Chris Ho
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55080206&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2017001543(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of CL2017001543A1 publication Critical patent/CL2017001543A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

<p>SE DIVULGAN FORMULACIONES FARMACÉUTICAS CON UN INHIBIDOR DE CINASA RELACIONADA CON TROPOMIOSINA ('INHIBIDOR DE TRK"). LAS FORMULACIONES FARMACÉUTICAS COMPRENDEN EN FORMULACIONES DE SUSPENSIÓN MICROCRISTALINA EN SU FORMA DE MONOHIDRATO, QUE MUESTRA CARACTERÍSTICAS MEJORADAS FRENTE A LA FORMA DE ANHIDRATO, Y EN FORMULACIONES DE LIBERACIÓN PROLONGADA. LAS FORMULACIONES FARMACÉUTICAS DE LIBERACIÓN PROLONGADA COMPRENDEN MICROESFERAS CARGADAS CON 3-(3- METOXI-4-((4-METOXTBENCIL)-OXI)BENCIL)-6-(1-METJL-1 H-PIRAZOL-4-II)-3H-IMIDAZO[4,5-B]PIRIDIN-2-AMINA.</p>
CL2017001543A 2014-12-18 2017-06-14 Formulaciones farmacéuticas de inhibidores de la cinasa relacionada con tropomiosina (trk) CL2017001543A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462093801P 2014-12-18 2014-12-18

Publications (1)

Publication Number Publication Date
CL2017001543A1 true CL2017001543A1 (es) 2018-03-16

Family

ID=55080206

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017001543A CL2017001543A1 (es) 2014-12-18 2017-06-14 Formulaciones farmacéuticas de inhibidores de la cinasa relacionada con tropomiosina (trk)

Country Status (22)

Country Link
US (4) US10219998B2 (es)
EP (1) EP3233057A2 (es)
JP (1) JP6606183B2 (es)
KR (1) KR102561692B1 (es)
CN (2) CN110950862B (es)
AR (1) AR103176A1 (es)
AU (1) AU2015364557C1 (es)
BR (1) BR112017012566B1 (es)
CA (1) CA2970938C (es)
CL (1) CL2017001543A1 (es)
CO (1) CO2017007118A2 (es)
EA (1) EA201791336A1 (es)
IL (1) IL252901B (es)
MA (1) MA40698A3 (es)
MX (2) MX2017008058A (es)
MY (1) MY195799A (es)
NZ (1) NZ733825A (es)
PH (1) PH12017501121B1 (es)
SG (1) SG11201704872RA (es)
TN (1) TN2017000234A1 (es)
TW (2) TWI780438B (es)
WO (1) WO2016100677A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI731317B (zh) 2013-12-10 2021-06-21 美商健臻公司 原肌球蛋白相關之激酶（ｔｒｋ）抑制劑
CN110950862B (zh) 2014-12-18 2024-01-05 建新公司 原肌球蛋白相关激酶(trk)抑制剂的药物制剂
CN110156813B (zh) * 2018-02-13 2023-07-25 北京诺诚健华医药科技有限公司 作为trk抑制剂的杂环化合物
AR114110A1 (es) 2018-02-28 2020-07-22 Lilly Co Eli Anticuerpo anti-trka
EP4180428A1 (en) * 2021-11-12 2023-05-17 Genzyme Corporation Crystalline imidazo[4,5-b]pyridine compound, pharmaceutical compositions, and their use in treating medical conditions
CN114712365B (zh) * 2022-06-07 2022-08-23 山东绿叶制药有限公司 Trk抑制剂在制备治疗迟发性运动障碍药物中的应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60158180A (ja) 1984-01-30 1985-08-19 Sumitomo Chem Co Ltd ベンズイミダゾ−ル誘導体、その製造法およびそれを有効成分とする殺虫、殺ダニ剤
US4612323A (en) 1983-06-27 1986-09-16 Sumitomo Chemical Company, Limited Insecticidal and acaricidal derivatives of 1-benzylbenzimidazole
JPS6117569A (ja) 1984-07-03 1986-01-25 Sumitomo Chem Co Ltd ベンズイミダゾ−ル誘導体およびそれを有効成分とする殺ダニ剤
JPS6117569U (ja) 1984-07-05 1986-02-01 エヌオーケー株式会社 バルブ装置
JPS61151176A (ja) 1984-12-24 1986-07-09 Sumitomo Chem Co Ltd ベンズイミダゾール誘導体およびそれを有効成分とする殺虫、殺ダニ剤
DE4219534A1 (de) 1992-02-19 1993-12-16 Thomae Gmbh Dr K Substituierte Biphenylylderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DK154092D0 (da) 1992-12-23 1992-12-23 Neurosearch As Imidazolforbindelser, deres fremstilling og anvendelse
US5702637A (en) 1995-04-19 1997-12-30 Minnesota Mining And Manufacturing Company Liquid crystal compounds having a chiral fluorinated terminal portion
US6348474B1 (en) 1997-06-27 2002-02-19 Fujisawa Pharmaceutical Co., Ltd. Sulfonamide compounds and medicinal use thereof
NZ502642A (en) 1997-07-03 2002-06-28 Du Pont Pharm Co Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
US7030150B2 (en) 2001-05-11 2006-04-18 Trimeris, Inc. Benzimidazole compounds and antiviral uses thereof
CN1551866A (zh) 2001-08-09 2004-12-01 СҰҩƷ��ҵ��ʽ���� 羧酸衍生物化合物及包含这些化合物为活性成分的药物
GB0122190D0 (en) 2001-09-14 2001-10-31 Qinetiq Ltd Novel compounds
US20040002145A1 (en) 2002-03-18 2004-01-01 Shewchuk Lisa Marie Crystal structure of liganded cFMS kinase domain
EP1505966A4 (en) 2002-05-10 2006-08-30 Bristol Myers Squibb Co 1,1-DISUBSTITUTED CYCLOALKYL DERIVATIVES AS FACTOR XA HEMMER
FR2852957B1 (fr) 2003-03-31 2005-06-10 Sod Conseils Rech Applic Nouveaux derives d'imidazo-pyridine et leur utilisation en tant que medicament
TWI332003B (en) 2004-01-30 2010-10-21 Lilly Co Eli Kinase inhibitors
EP1731524A4 (en) 2004-03-31 2009-05-20 Kissei Pharmaceutical PHENOLE DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE DERIVATIVE, AND ITS MEDICINAL USE
NZ550769A (en) 2004-05-07 2010-06-25 Warner Lambert Co 3- or 4-Monosubstituted phenol and thiophenol derivatives useful as H3 ligands
CA2587566A1 (en) 2004-11-18 2006-05-26 The Institutes For Pharmaceutical Discovery, Llc Heterocyclylbiphenyl derivates as protein tyrosine phosphatase inhibitors
DK1853588T3 (da) 2005-02-16 2008-09-15 Astrazeneca Ab Kemiske forbindelser
JP2006273879A (ja) 2005-03-25 2006-10-12 Fuji Photo Film Co Ltd カラー表示素子及びカラー表示方法
EP1935890B1 (en) 2005-09-30 2016-03-16 Msd K.K. 2-heteroaryl-substituted indole derivative
CN1947717B (zh) 2005-10-14 2012-09-26 卓敏 选择性抑制腺苷酸环化酶1的化合物在制备用于治疗神经性疼痛和炎性疼痛的药物中的应用
US7851484B2 (en) 2007-03-30 2010-12-14 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
JP2010524911A (ja) * 2007-04-18 2010-07-22 アストラゼネカ アクチボラグ ５−アミノピラゾール−３−イル−３Ｈ−イミダゾ［４，５−ｂ］ピリジン誘導体と癌の治療のためのその使用
EP2183255A4 (en) 2007-08-29 2011-06-15 Methylgene Inc METHOD AND INTERMEDIATE PRODUCTS FOR THE PREPARATION OF CONDENSED HETEROCYCLIC KINASE INHIBITORS
WO2010088518A2 (en) 2009-01-31 2010-08-05 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
SI2493895T1 (sl) 2009-10-29 2017-10-30 Vectura Limited Derivati heteroarila, ki vsebujejo N, kot inhibitorji JAK3 kinaze
WO2011058139A1 (en) 2009-11-12 2011-05-19 Selvita Sp. Z O. O. A compound, a process for its preparation, a pharmaceutical composition, use of a compound, a method for modulating or regulating serine/threonine kinases and a serine/threonine kinases modulating agent
US8604217B2 (en) 2009-11-12 2013-12-10 Selvita S.A. Compound, a process for its preparation, a pharmaceutical composition, use of a compound, a method for modulating or regulating serine/threonine kinases and a serine/threonine kinases modulating agent
US20130165426A1 (en) 2010-07-06 2013-06-27 Université de Montréal Imidazopyridine, imidazopyrimidine and imidazopyrazine derivatives as melanocortin-4 receptor modulators
MX2013011612A (es) 2011-04-05 2013-10-17 Pfizer Ltd Derivados de pirrolo[2,3-d]pirimidina como inhibidores de quinasa relacionados con tropomiosina.
CN104114553B (zh) 2011-12-12 2017-03-01 雷迪博士实验室有限公司 作为原肌球蛋白受体激酶(Trk)抑制剂的取代的吡唑并[1,5‑a]吡啶
WO2013176970A1 (en) * 2012-05-22 2013-11-28 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
JP6117569B2 (ja) 2013-02-28 2017-04-19 三甲株式会社 ボックスパレット
GB201321741D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
TWI731317B (zh) 2013-12-10 2021-06-21 美商健臻公司 原肌球蛋白相關之激酶（ｔｒｋ）抑制劑
CN110950862B (zh) 2014-12-18 2024-01-05 建新公司 原肌球蛋白相关激酶(trk)抑制剂的药物制剂
CN107197528B (zh) 2016-03-14 2020-12-25 华为技术有限公司 一种资源调度和分配的方法和装置

Also Published As

Publication number Publication date
TW201639837A (zh) 2016-11-16
MA40698A2 (fr) 2018-10-31
KR20170096160A (ko) 2017-08-23
MY195799A (en) 2023-02-21
TW202104225A (zh) 2021-02-01
KR102561692B1 (ko) 2023-07-28
AR103176A1 (es) 2017-04-19
JP2018503611A (ja) 2018-02-08
CA2970938A1 (en) 2016-06-23
CN110950862A (zh) 2020-04-03
US20240189223A1 (en) 2024-06-13
MA40698A3 (fr) 2020-01-31
BR112017012566B1 (pt) 2024-01-30
EP3233057A2 (en) 2017-10-25
AU2015364557C1 (en) 2021-11-18
US20200048222A1 (en) 2020-02-13
US20220110861A1 (en) 2022-04-14
IL252901B (en) 2020-10-29
US20180000728A1 (en) 2018-01-04
CN107231803B (zh) 2019-12-03
WO2016100677A3 (en) 2016-08-11
IL252901A0 (en) 2017-08-31
PH12017501121A1 (en) 2017-11-27
US11110055B2 (en) 2021-09-07
CN110950862B (zh) 2024-01-05
TN2017000234A1 (en) 2018-10-19
US10219998B2 (en) 2019-03-05
PH12017501121B1 (en) 2017-11-27
WO2016100677A2 (en) 2016-06-23
SG11201704872RA (en) 2017-07-28
AU2015364557A1 (en) 2017-08-03
TWI696621B (zh) 2020-06-21
CN107231803A (zh) 2017-10-03
NZ733825A (en) 2022-02-25
CO2017007118A2 (es) 2017-08-18
US11793749B2 (en) 2023-10-24
BR112017012566A2 (pt) 2018-01-02
AU2015364557B2 (en) 2021-04-29
MX2020013015A (es) 2021-02-22
MX2017008058A (es) 2017-09-28
CA2970938C (en) 2023-04-18
JP6606183B2 (ja) 2019-11-13
TWI780438B (zh) 2022-10-11
EA201791336A1 (ru) 2017-10-31

Similar Documents

Publication Publication Date Title
CL2017001543A1 (es) Formulaciones farmacéuticas de inhibidores de la cinasa relacionada con tropomiosina (trk)
DK3611174T3 (da) [1,2,4]triazolo[1,5-c]pyrimidinderivat som a2a-receptorinhibitor
WO2017108723A3 (en) PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS
HK1258857A1 (zh) 作為lrrk2抑制劑的新穎咪唑並[4，5-c]喹啉和咪唑並[4，5- c][1，5]萘啶衍生物
IL254224A0 (en) 7-substituted 5-alkyl-[4,2,1]triazolo[5,1-a]pyrimidine derivatives as pde2 inhibitors
EP3478687A4 (en) PYRAZOLOPYRIMIDINE DERIVATIVES AS A KINASE INHIBITOR
ECSP15043696A (es) Compuestos de heteroarilo y sus usos
CL2014002412A1 (es) Compuestos derivados de pirido[4,3-d]pirimidina, como inhibidores de mek; composicion farmaceutica que los comprende; y su uso para el tratamiento de enfermedades inflamatorias, infecciones, trastornos autoinmunes, enfermedades metabolicas y enfermedades malignas, entre otras.
NI201500119A (es) Compuestos de heteroarilo y sus usos
EP3154970A4 (en) Pyrrolo[2,3-c]pyridines as imaging agents for neurofibrilary tangles
IL266305B (en) History of [4,2,1]triazolo[5,1-a]pyrimidine as pde2 inhibitors
SI2776442T1 (sl) Derivati (1,2,3)triazolo(4,5-d)pirimidina kot agonisti kanabinoidnega receptorja 2
DK2861608T3 (da) Prodrug-derivater af (e)-n-methyl-n-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamid
SG11202005264PA (en) Pyrrolo(pyrazolo)pyrimidine derivative as lrrk2 inhibitor
DK3478681T3 (da) 1h-pyrazolo[4,3-b]pyridiner som pde1-inhibitorer
SI2782915T1 (sl) Derivati (1,2,3)triazolo(4,5-d)pirimidina kot agonisti agonistov kanabinoidnega receptorja 2
EP3159341B8 (en) Pyridino[1,2-a]pyrimidone analogue used as pi3k inhibitor
ZA201808014B (en) Adenine derivatives as protein kinase inhibitors
DK3840832T3 (da) Imidazo[1,2-b]pyridaziner som trk-inhibitorer
DK3083627T3 (da) [1,2,4]triazol[1,5-a]pyrimidinderivater som protozoiske proteasominhibitorer til behandling af parasitsygdomme, såsom leishmaniasis
IL269214B (en) Novel imidazo[5,4-c]quinoline derivatives as lrrk2 inhibitors
EP3196199A4 (en) Substituted n-(pyrrolidine-3-yl)-7h-pyrrolo[2,3-d]pyrimidine-4-amine as janus kinase inhibitor
EP3406612A4 (en) CARBOLINE DERIVATIVE AS A BROMODOMAIN INHIBITOR
DK3679042T3 (da) Imidazo[1,5-A]pyrazin-derivater som PI3Kdelta-inhibitorer
DK3823972T3 (da) Imidazo[1,2-b]pyridazinderivater som trk-inhibitorer